Thanks for the update!I think (like many of us perhaps!) I got...

Thanks for the update!

I think (like many of us perhaps!) I got carried away with the Lupin result and was half expecting my holding to 10x by April and take my gains on to new investments noting i've been a holder since 2017.

Clearly the picture here is so much bigger than just late state prostate cancer (however important this still may be). The drawback of this is that to achieve that 10x, 20x, or even 30x some of us may have thought might be coming, we will likely need to be patient and wait years. These studies take 2-3 years to complete, along with IP issues and marketing and reaching agreements for Veyonda - realistically the ideal time to continue to hold might be another 5-10 years.

I have a lot of faith in Mr Kelly and the team and most certainly in Veyonda. Seeing the share price come back down to $0.80 (when i'd have thought $1.80 would be more likely by now) has been a sobering reminder that share price isn't important right now as long as Noxopharm continue to deliver...whatever the time frame may be! The share price will eventually display its value as it becomes more apparent that Veyonda is an industry changing drug.

So, given I don't need the capital right now and I am a buy and hold investor, I will be patient and trust in Noxopharm.

Thanks

p.s I am a finance guy and as far away removed from the medical world as one can be, so any medical professionals i'd love to get your take on this too.